Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biofrontera (BFRI) Cost of Revenue (2020 - 2025)

Biofrontera (BFRI) has 6 years of Cost of Revenue data on record, last reported at $2.0 million in Q3 2025.

  • For Q3 2025, Cost of Revenue rose 2590.79% year-over-year to $2.0 million; the TTM value through Sep 2025 reached $13.2 million, down 36.14%, while the annual FY2024 figure was $18.6 million, 6.67% up from the prior year.
  • Cost of Revenue reached $2.0 million in Q3 2025 per BFRI's latest filing, down from $2.6 million in the prior quarter.
  • Across five years, Cost of Revenue topped out at $17.5 million in Q4 2022 and bottomed at $41000.0 in Q3 2021.
  • Average Cost of Revenue over 5 years is $3.0 million, with a median of $181000.0 recorded in 2021.
  • Peak YoY movement for Cost of Revenue: surged 9554.7% in 2022, then crashed 98.51% in 2024.
  • A 5-year view of Cost of Revenue shows it stood at $181000.0 in 2021, then soared by 9554.7% to $17.5 million in 2022, then crashed by 30.32% to $12.2 million in 2023, then tumbled by 56.71% to $5.3 million in 2024, then plummeted by 61.2% to $2.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cost of Revenue were $2.0 million in Q3 2025, $2.6 million in Q2 2025, and $3.3 million in Q1 2025.